Start here if you're new
what it is
Avenue Therapeutics is a micro-cap biotech trying to turn a few neurology and rare-disease drug assets into something commercial.
how it gets paid
Last year Avenue Therapeutics made n/a in revenue. other revenue was the main engine at $1M, or 100% of sales.
what just happened
The latest quarter showed $1M of revenue and a loss of $0.71 per share, which is still tiny-business biotech math.
At a glance
C+ balance sheet — struggling to keep the lights on
5/100 earnings predictability — expect surprises
-$15.79 fy2024 eps est
0.9 beta
~$1M market cap
xvary composite: 27/100 — weak
What they do
Avenue Therapeutics is a micro-cap biotech trying to turn a few neurology and rare-disease drug assets into something commercial.
The moat is not scale. It is optionality. You are paying roughly $1 million in market value for a company tied to drug assets that include up to $82 million in possible BAER-101 milestones, though those payments are contingent and not guaranteed.
How they make money
n/a
annual revenue
other revenue
$1M
iv tramadol
$0M
baer-101 economics
$0M
atx-04
$0M
The products that matter
legacy lead asset
IV Tramadol
1 lead pain program
This was the original core asset, and with only about $1 million of latest-quarter revenue across the whole company, any successful path here would matter a lot.
lead asset
milestone upside
BAER-101
up to $82M milestones
BAER-101 rights were acquired by Axsome through Baergic, and shareholders may receive up to $82 million if development, regulatory, and sales milestones are hit.
up to $82M
new rare-disease bet
ATX-04
licensed in 2026
ATX-04 gives Avenue a fresh clinical angle in Pompe disease, but you are looking at an early-stage asset inside a company with just 2 employees.
2026 license
Key numbers
-$15.79
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ATXI right now.
source: institutional data · return history unavailable
What just happened
reported a loss
The latest quarter showed $1M of revenue and a loss of $0.71 per share, which is still tiny-business biotech math.
Revenue exists, but the company is still defined by losses. Contrast helps: latest-quarter revenue was $1 million, while FY2024 EPS was estimated at -$15.79.
$1M
revenue
$0.71
eps
238%
eps vs. last year
the number that mattered
$1 million of quarterly revenue matters because it shows the company has some reported sales or other revenue, but nowhere near enough to offset recurring losses.
source: SEC filing data and consensus figures, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Avenue's biggest threat is not competition. It is running out of room before the science pays.
high
Tiny balance-sheet cushion
The company had about $3.709 million of cash in a recent quarter, according to a cited financial-health snippet. With only about $1 million of latest-quarter revenue and continuing losses, that cushion looks thin.
A $1 million cash burn would equal about 27% of that $3.709 million cash balance.
high
Still losing money
FY2024 EPS was estimated at -$15.79, and the latest quarter showed EPS of -$0.71. Earnings per share → profit per share → so what: you are still funding losses, not buying a self-funding business.
Another year near -$15.79 EPS would keep dilution risk elevated for a stock priced around $0.27.
med
Pipeline concentration
Avenue lists a small set of named assets: IV tramadol, BAER-101, and ATX-04. If one program slips, there is not a broad product base to absorb the hit.
Losing access to the up to $82 million BAER-101 milestone stream would erase the largest disclosed economic upside tied to a single asset.
The risk math is blunt. You have a roughly $1 million company trying to finance biotech losses with very little margin for error.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next earnings report
The next earnings report on March 30, 2026 matters because another quarter near the latest -$0.71 EPS would reinforce financing risk for a stock around $0.27.
risk
bloomberg news - advisor perspectives
A broader risk-off tape matters more when your market cap is only about $1 million, because even a 20% move changes equity value by roughly $0.2 million.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
earnings predictability
5 / 100
earnings can be harder to predict — expect surprises.
source: institutional data
Institutional activity
institutional ownership data for ATXI is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$0
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive